{"id":"hmg-coa-inhibitor","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Muscle pain or myalgia"},{"rate":"1-3%","effect":"Elevated liver enzymes"},{"rate":"<0.1%","effect":"Rhabdomyolysis"},{"rate":"1-2%","effect":"Headache"},{"rate":"1-2%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting HMG-CoA reductase, these drugs reduce the production of mevalonate and downstream cholesterol synthesis in hepatocytes. This leads to upregulation of LDL receptors on liver cells, increasing clearance of LDL cholesterol from the bloodstream and lowering serum cholesterol levels. They are commonly known as statins and are among the most widely used lipid-lowering agents.","oneSentence":"HMG-CoA inhibitors block the enzyme HMG-CoA reductase, which catalyzes an early and rate-limiting step in cholesterol synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:44.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT07089589","phase":"","title":"Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-01-02","conditions":"Major Adverse Cardiovascular Events, Liver Transplantation","enrollment":6871},{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT07459972","phase":"PHASE4","title":"Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-03-15","conditions":"Liver Cirrhosis, Portal Hypertension Related to Cirrhosis","enrollment":22},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT05488431","phase":"PHASE2","title":"Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)","status":"RECRUITING","sponsor":"Priscilla Hsue, MD","startDate":"2023-03-01","conditions":"Dyslipidemias, Cardiovascular Diseases, HIV Infections","enrollment":121},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT06902740","phase":"PHASE4","title":"PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque","enrollment":300},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":"Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous","enrollment":1695},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":"Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder","enrollment":59},{"nctId":"NCT06784557","phase":"PHASE4","title":"Effect of Ezetimibe on Gut Microbiota","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-02-28","conditions":"Atherosclerotic Cardiovascular Disease With Dyslipidemia","enrollment":110},{"nctId":"NCT06730802","phase":"NA","title":"Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Medical University","startDate":"2025-01-01","conditions":"Myocardial Ischaemic Syndrome, Coronary Heart Disease","enrollment":400},{"nctId":"NCT04826237","phase":"PHASE4","title":"Oral Statins and Protection From Hearing Loss","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-02-09","conditions":"Sudden Sensorineural Hearing Loss","enrollment":100},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT05419583","phase":"NA","title":"Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-11-14","conditions":"Myocardial Infarction Type 2","enrollment":60},{"nctId":"NCT06520904","phase":"PHASE4","title":"Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography","status":"RECRUITING","sponsor":"First Affiliated Hospital of Xinjiang Medical University","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Optical Coherence Tomography","enrollment":396},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT05782881","phase":"NA","title":"High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-01-15","conditions":"Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":16000},{"nctId":"NCT04986241","phase":"","title":"The Association of Statins on Cardiorespiratory Fitness and Exercise Adaptation","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-09-20","conditions":"Statin Adverse Reaction","enrollment":18557},{"nctId":"NCT06134635","phase":"","title":"Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-12-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT05623995","phase":"PHASE4","title":"Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)","status":"UNKNOWN","sponsor":"Lin Zhao","startDate":"2022-12-15","conditions":"In-stent Restenosis, Major Adverse Cardiovascular Events","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT04591808","phase":"PHASE3","title":"Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia","status":"TERMINATED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-09-09","conditions":"Dyslipidemias, Hypertension","enrollment":146},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT04608474","phase":"PHASE4","title":"Lipid Management in Renal Transplant Recipients Using Evolocumab.","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-17","conditions":"Hyperlipidemias","enrollment":120},{"nctId":"NCT02713945","phase":"PHASE3","title":"Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-01-25","conditions":"Noonan Syndrome","enrollment":53},{"nctId":"NCT05802108","phase":"PHASE4","title":"Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy","status":"UNKNOWN","sponsor":"Zibo Central Hospital","startDate":"2022-07-01","conditions":"Adverse Effect of Cardiovascular Medications (Diagnosis)","enrollment":60},{"nctId":"NCT00309257","phase":"PHASE2","title":"Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2004-01","conditions":"Alport Syndrome","enrollment":9},{"nctId":"NCT02341924","phase":"NA","title":"Validating the \"Foods for Health\" Portfolio of Functional Food Products","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2015-09","conditions":"Hypercholesterolemia","enrollment":60},{"nctId":"NCT03933293","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-05-13","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT04512404","phase":"","title":"Endothelial Microparticles as Potential Biomarkers of Endothelial Dysfunction","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2016-10-13","conditions":"Endothelial Dysfunction","enrollment":48},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT05582317","phase":"NA","title":"Efficacy of Combination of Biodentine and Simvastatin as a Pulp Capping Materials in Vital Pulpotomy of Primary Molars","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2021-05-23","conditions":"Pulpitis - Irreversible","enrollment":20},{"nctId":"NCT04426084","phase":"","title":"Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2020-03-01","conditions":"COVID-19","enrollment":22784},{"nctId":"NCT03611010","phase":"PHASE2","title":"Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2018-08-07","conditions":"Hypercholesterolemia, Dyslipidemias","enrollment":40},{"nctId":"NCT05298475","phase":"PHASE4","title":"Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Acute Coronary Syndrome","enrollment":100},{"nctId":"NCT01508468","phase":"PHASE3","title":"Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-01-17","conditions":"Idiopathic Membranous Nephropathy","enrollment":80},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT04851769","phase":"PHASE4","title":"Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-03-02","conditions":"Randomized Controlled Trials","enrollment":60},{"nctId":"NCT04776889","phase":"PHASE4","title":"The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-01-15","conditions":"Prostate Cancer Metastatic","enrollment":70},{"nctId":"NCT04705909","phase":"PHASE2, PHASE3","title":"Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-01-15","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT02634580","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-27","conditions":"Hypercholesterolemia","enrollment":61},{"nctId":"NCT04085016","phase":"","title":"Effect of HMG-CoA Reductase Inhibitors on the Meibomian Gland Morphology in Patients With Meibomitis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2016-12-08","conditions":"Meibomian Gland Dysfunction, Meibomitis, Dyslipidemias","enrollment":98},{"nctId":"NCT01695954","phase":"PHASE1","title":"Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-05","conditions":"Hyperlipidemia, HIV","enrollment":34},{"nctId":"NCT01837069","phase":"PHASE4","title":"Risk Factor Control Before Orthopedic Surgery","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2014-02","conditions":"Osteoarthritis, Cardiovascular Disease","enrollment":198},{"nctId":"NCT01763905","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-24","conditions":"Hyperlipidemia","enrollment":307},{"nctId":"NCT03573102","phase":"PHASE4","title":"Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients","status":"UNKNOWN","sponsor":"Nahla H Tohami","startDate":"2018-06-20","conditions":"Diabetic Nephropathies","enrollment":60},{"nctId":"NCT03370705","phase":"PHASE3","title":"Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone","status":"UNKNOWN","sponsor":"Alfa Wassermann Tunisia","startDate":"2019-01-31","conditions":"Peripheral Arterial Obstructive Disease","enrollment":156},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":"Hyperlipidemias","enrollment":342},{"nctId":"NCT02563860","phase":"PHASE2","title":"Pharmacological Treatment of Rett Syndrome With Statins","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2015-07","conditions":"Rett Syndrome","enrollment":20},{"nctId":"NCT02290106","phase":"NA","title":"Effects of Pitavastatin on Insulin Sensitivity and Liver Fat","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-03-02","conditions":"Obesity, Fatty Liver, Nonalcoholic","enrollment":50},{"nctId":"NCT03750760","phase":"PHASE4","title":"Early Alirocumab to Reduce LDL-C in Myocardial Infarction","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2020-01","conditions":"Myocardial Infarction, Dyslipidemias","enrollment":""},{"nctId":"NCT02674204","phase":"PHASE2","title":"STOP Heart Disease in Breast Cancer Survivors Trial","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2016-05-05","conditions":"Breast Cancer, Heart Disease, Cardiotoxicity","enrollment":2},{"nctId":"NCT02839902","phase":"PHASE4","title":"Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-27","conditions":"Hyperlipidemia","enrollment":53},{"nctId":"NCT01212900","phase":"PHASE4","title":"Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-09-30","conditions":"Atherosclerosis, Hypercholesterolemia","enrollment":230},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT00263393","phase":"PHASE4","title":"Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2005-12","conditions":"Myocardial Infarction, Angina Pectoris, Cerebrovascular Accidents","enrollment":3712},{"nctId":"NCT01581476","phase":"PHASE3","title":"Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2009-01","conditions":"Type 1 Diabetes","enrollment":443},{"nctId":"NCT00221104","phase":"PHASE3","title":"Japan Statin Treatment Against Recurrent Stroke (J-STARS)","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2004-03-01","conditions":"Ischemic Stroke","enrollment":1578},{"nctId":"NCT01175148","phase":"PHASE2","title":"Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2010-07","conditions":"Graft vs Host Disease","enrollment":60},{"nctId":"NCT00580970","phase":"PHASE2","title":"Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2007-04","conditions":"Prostate Cancer","enrollment":73},{"nctId":"NCT00361530","phase":"PHASE3","title":"Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2004-03","conditions":"Ischemic Stroke","enrollment":854},{"nctId":"NCT00361699","phase":"PHASE3","title":"hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2004-03","conditions":"Ischemic Stroke","enrollment":1095},{"nctId":"NCT00570752","phase":"PHASE2","title":"Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":"Vascular Diseases","enrollment":72},{"nctId":"NCT02432040","phase":"PHASE2","title":"Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Philippine Dermatological Society","startDate":"2013-02","conditions":"Psoriasis","enrollment":28},{"nctId":"NCT00929734","phase":"PHASE2","title":"Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":99},{"nctId":"NCT00554502","phase":"PHASE3","title":"Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2008-02","conditions":"IgA Nephropathy","enrollment":148},{"nctId":"NCT01400009","phase":"NA","title":"Vitamin D Replacement in Statin-Induced Myopathy","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2010-10","conditions":"HMG COA Reductase Inhibitor Adverse Reaction","enrollment":""},{"nctId":"NCT01602913","phase":"","title":"Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12","conditions":"Depression, Postpartum","enrollment":1},{"nctId":"NCT00064792","phase":"PHASE2","title":"Simvastatin Therapy in Smith-Lemli-Opitz Syndrome","status":"COMPLETED","sponsor":"Forbes Porter, M.D.","startDate":"2003-07","conditions":"Smith-Lemli-Opitz Syndrome","enrollment":23},{"nctId":"NCT00828282","phase":"PHASE1","title":"High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL","status":"COMPLETED","sponsor":"John Haslip","startDate":"2009-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":3},{"nctId":"NCT00065806","phase":"PHASE3","title":"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)","status":"COMPLETED","sponsor":"Laura Schanberg","startDate":"2003-09","conditions":"Lupus Erythematosus, Systemic","enrollment":221},{"nctId":"NCT00920101","phase":"PHASE4","title":"Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging","status":"UNKNOWN","sponsor":"National Defense Medical College, Japan","startDate":"2009-06","conditions":"Atherosclerosis, Inflammation","enrollment":30},{"nctId":"NCT01446679","phase":"","title":"Special Drug Use-Results Survey of Lipitor Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09","conditions":"Hypercholesterolemia","enrollment":24050},{"nctId":"NCT01257971","phase":"","title":"Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-01","conditions":"Hypercholesterolaemia","enrollment":1868},{"nctId":"NCT01508663","phase":"PHASE4","title":"The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-08","conditions":"Coronary Artery Disease","enrollment":1600},{"nctId":"NCT00117494","phase":"PHASE4","title":"Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-10","conditions":"Hyperlipidemia, HIV Infections","enrollment":86},{"nctId":"NCT00396721","phase":"PHASE2","title":"Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy","status":"COMPLETED","sponsor":"Josep m Cruzado","startDate":"2006-01","conditions":"Glomerulonephritis, IGA, Nephropathy, IGA, IGA Nephropathy","enrollment":23},{"nctId":"NCT00329160","phase":"PHASE4","title":"Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Hypercholesteremia","enrollment":214},{"nctId":"NCT00555230","phase":"PHASE2","title":"Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-07","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00382161","phase":"PHASE3","title":"Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors","status":"WITHDRAWN","sponsor":"University Hospital, Saarland","startDate":"2006-10","conditions":"Impotence","enrollment":20},{"nctId":"NCT00024531","phase":"PHASE2","title":"Lipitor as a Treatment for Alzheimer's Disease","status":"COMPLETED","sponsor":"Institute for the Study of Aging (ISOA)","startDate":"2000-10","conditions":"Alzheimer Disease","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"HMG CoA inhibitor","genericName":"HMG CoA inhibitor","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HMG-CoA inhibitors block the enzyme HMG-CoA reductase, which catalyzes an early and rate-limiting step in cholesterol synthesis. Used for Hypercholesterolemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}